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Steroid-free regimen is increasingly employed in kid-
ney transplant recipients across transplant centers.
However, concern remains because of the unknown
impact of such an approach on long-term graft and
patient survival. We studied the outcomes of steroid-
free immunosuppression in a population-based U.S.
cohort of kidney transplant recipients. All adult soli-
tary kidney transplant recipients engrafted between
January 1, 2000 and December 31, 2006 were strat-
ified according to whether they were selected for
a steroid-free or steroid-containing regimen at dis-
charge. Multivariate Cox regression models were used
to estimate graft and patient survival. The impact
of the practice pattern on steroid use at individual
transplant centers was analyzed. Among 95755 kid-
ney transplant recipients, 17.2% were steroid-free at
discharge (n = 16491). Selection for a steroid-free
regimen was associated with reduced risks for graft
failure and death at 1 year (HR 0.78, 95% CI 0.72–
0.85, and HR 0.73, 95% CI 0.65–0.82, respectively,
p < 0.0001) and 4 years (HR 0.83, 95% CI 0.78–0.87, and
HR 0.76, 95% CI 0.71–0.83, respectively, p < 0.0001).
This association was mostly observed at individual
centers where less than 65% of recipients were dis-
charged on the steroid-containing regimen. De novo
steroid-free immunosuppression as currently practiced
in the United States appears to carry no increased risk
of adverse clinical outcomes in the intermediate term.
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Introduction
Steroid therapy has been a core component of trans-
plant immunotherapy since early stages of clinical kidney
transplantation and credited for some role in prevention
and treatment of acute rejection (1–4). However, chronic
steroid therapy is associated with numerous adverse ef-
fects, including worsening hypertension and dyslipidemia,
increased susceptibility to infection, development of dia-
betes mellitus, osteoporosis, weight gain, etc. (5–7). These
adverse effects may have contributed to the development
and worsening of cardiovascular disease in kidney trans-
plant recipients (8). Thus, the effort to develop steroid-
free immunosuppression has continued for nearly three
decades. Such enthusiasm waned in the mid-1980s fol-
lowing the results of the Multicenter Study of 523 kidney
transplant recipients in Canada in the 1980s and other stud-
ies which showed the increased risk of acute rejection and
graft loss in the absence of steroid in low-risk kidney trans-
plant recipients (9–12).
The introduction of more effective antirejection drugs, no-
tably mycophenolate mofetil (MMF) and thymoglobulin, in
the late 1990s reinvigorated the testing of newer combina-
tions of immunosuppressive agents with early withdrawal
or avoidance of steroid. More recent experiences with early
steroid withdrawal have yielded comparable results with
steroid-containing regimens (13–18). The FREEDOM Trial
showed no differences in the composite endpoint of acute
rejection rate, recipient and graft survival at 12 months
between steroid-withdrawal and steroid-containing regi-
mens, but found a significant increase in the incidence of
early acute rejection in the steroid-withdrawal group (17).
On the other hand, the steroid-withdrawal group in the
FREEDOM Trial was associated with a small reduction in
the rate of metabolic complications, as seen in some other
studies (15,17). There is no conclusive data on whether
the use of a steroid-free regimen in kidney transplantation
leads to improvement in patient and graft survival prin-
cipally because prior studies lacked the necessarily large
sample size and long duration of follow-up to yield defini-
tive results on the endpoints of death and graft failure.
Concern remains whether the steroid-free regimen could
lead to slow deterioration of renal allograft function and
allograft loss over the years, thus counterproductive of any
potential benefits observed in various clinical trials during
short-time follow-up.
The present study is a retrospective cohort evaluation
of U.S. transplant registry data to address the following
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questions: (1) whether steroid-free regimen was associ-
ated with a different rate of short- and intermediate-term
patient and graft survival, respectively; (2) which types
of patients were selected for steroid-free regimen and
whether they were systematically different from recipients
treated with steroid-containing regimen; (3) what is the
trend in the use of steroid-free regimen and (4) whether
there were differences in the induction and maintenance




The Scientific Registry of Transplant Recipients (SRTR) provided data col-
lected by the Organ Procurement and Transplantation Network (OPTN) from
all U.S. kidney transplant programs. The study population consisted of sub-
jects aged ≥ 18 years at the time of transplantation who received a solitary
kidney transplant from either a deceased or living donor between January
1, 2000 and December 31, 2006 in the United States and who were alive
with a functioning graft at discharge from the transplant surgery and had
at least one maintenance immunosuppresion drug reported at the time of
discharge.
Analytic methods
Subjects were classified as being treated with steroid-free maintenance
immunosuppression if it was recorded on the transplant registration form
that maintenance immunosuppression does not include any steroid and if
the recipient’s list of immunosuppressive medications determined at the
time of discharge from the transplant surgery did not include steroid. This
definition was not conditioned on the use of steroid while recipients were
still in the hospital and data on changes in maintenance regimen that oc-
curred after initial discharge were not used to classify study subjects. Thus,
this is observational with ‘as treated’ analysis using the maintenance im-
munosuppressive regimen at the time of discharge from the initial trans-
plant hospitalization as the basis of subject stratification. Subjects were
followed with interval data collection at 6 and 12 months posttransplanta-
tion and annually thereafter until the occurrence of death, graft failure or
end of study period (December 31, 2006). The relationship between steroid-
free immunosuppression on graft and patient survival was estimated with
Cox proportional hazards regression models of time to graft failure and
time to death with an indicator variable for ‘discharge without steroid’ as
a covariate. Covariates included in all Cox regression models are grouped
as recipient, donor or transplant characteristics. The recipient variables in-
cluded induction regimen, nonsteroid regimen, age, race/ethnicity, gender,
source of payment (public, private or missing), body mass index, primary
diagnosis as etiology of end-stage renal disease (ESRD), hepatitis C status
(antibody positivity), years of ESRD prior to transplant, peak panel reac-
tive antibodies (PRA), previous transplant and functional status at trans-
plant. Donor characteristics common to both living and deceased donor
included age, race/ethnicity and gender. For living donor it also included
the relationship between donor and recipient, while for deceased donor it
included, in addition, the cause of death, history of diabetes mellitus and
hypertension, hepatitis C status (antibody positivity), serum creatinine at
the time of donation, donation after cardiac death (DCD) and expanded cri-
teria donor (ECD). Covariates related to the transplant included the ratio of
donor’s weight to recipient’s, HLA mismatch and cold ischemia time. For
deceased donor, the indicators for machine preservation of the kidney and
donor service area (DSA) were also included. For the graft survival anal-
ysis, death with a function graft was censored since the purpose of this
analysis was to illustrate the relationship between steroid use and graft
outcome.
Since the decision to treat a recipient with or without a steroid-free main-
tenance regimen is both a function of the recipient characteristics and the
practice pattern at individual transplant centers, we examined the ‘center
effect’ of the steroid practice pattern with an indicator variable in which
the fraction of transplant recipients at a particular transplant center were
discharged without steroid from the calendar year in which each index kid-
ney transplant was performed. This center-level variable was created for
each subject in the study and incorporated into the Cox regression model
of individual-level data, that is, recipients were clustered within transplant
center.
Subjects were also classified according to the induction immunosuppres-
sion given at the time of transplantation and according to the other mainte-
nance immunosuppressive drugs received at discharge from the initial trans-
plant hospitalization. The induction regimens were classified as yes and
no, with yes category including rabbit antithymocyte globulin (Thymoglob-
ulin, Genzyme, Cambridge, MA), anti-IL-2 receptor antibodies (baxiliximab,
Simulect, Norvatis, Basel, Switzerland, and daclizumab, Zanepax, Roche
Pharmaceuticals, Nutley, NJ) and alemtuzumab (Campath, Bayer Healthcare
Pharmaceuticals, Wayne, NJ). The maintenance regimens were classified
into combination of tacrolimus (Prograf, Astella, Tokyo, Japan) with MMF
(Cellcept, Roche Pharmaceuticals), cyclosporine with MMF, tacrolimus with
either sirolimus (Rapamune, Wyeth, Madison, NJ) or everolimus (Certican,
Norvatis) and cyclosporine with either sirolimus or everolimus. All others in-
cluded a large number of combinations being used in the context of clinical
trials and were grouped as ‘all other regimens’.
All analyses were performed using SAS version 9.1.
Results
The study cohort consisted of 95755 recipients who re-
ceived a solitary kidney transplant from living or deceased
donors between January 1, 2000 and December 31, 2006
and who met inclusion criteria described in the Materials
and methods section. Of these, 17.2% (n = 16491) were
discharged on steroid-free maintenance immunosuppres-
sion (group 1) and the remaining 82.8% (n = 79264) were
discharged with a maintenance regimen that included a
steroid preparation (group 2). Table 1 shows the baseline
recipient and donor characteristics of the two study groups.
There were notable differences in some of the character-
istics related to recipients and donors between the two
study groups. Subjects discharged on the steroid-free reg-
imen had a higher mean age (49.9 ± 13.5 vs. 48.5 ± 13.4,
p < 0.0001) and weight (BMI: 27.3 ± 5.6 vs. 26.9 ± 5.4,
p < 0.0001) at transplantation, included fewer African
American recipients (21.1% vs. 24.4%, p < 0.0001) but
had a higher prevalence of diabetes mellitus as a cause of
ESRD (24.9% vs. 22.8%, p < 0.0001). Subjects discharged
on the steroid-free regimen had spent less time on dialysis
(3.1 ± 4.0 years vs. 3.8 ± 4.6, p < 0.0001), had an im-
proved functional status at transplantation (NYHA I and II:
89.7% vs. 84.6%, p < 0.0001), were more likely to be first
transplant recipients (90.7% vs. 85.4%, p < 0.0001) and
were more likely to have received their kidney transplant
from a living donor (47.3% vs. 40.3%, p < 0.0001).
American Journal of Transplantation 2009; 9: 160–168 161
Luan et al.
Table 1: Descriptive statistics for selected recipient, donor and transplant characteristics
Group 1 Group 2
(N = 16 491) (N = 79 264) p-Value
Recipient characteristics
Age (years ± SD) 49.9 ± 13.5 48.5 ± 13.4 <0.0001
Male (%) 61.4 59.7 <0.0001
African American (%) 21.1 24.4 <0.0001
Primary diagnosis <0.0001
DM (%) 24.9 22.8
HTN (%) 22.8 22.0
GN (%) 25.3 27.7
PCKD (%) 10.6 9.3
Others (%) 16.4 18.2
First transplant (%) 90.7 85.4 <0.0001
Duration on dialysis (years) 3.1 ± 4.0 3.8 ± 4.6 <0.0001
Body mass index (BMI) at transplant 27.3 ± 5.6 26.9 ± 5.4 <0.0001





Functional status (NYHA I and II)(%) 89.7 84.6 <0.0001
HCV-positive serology (%) 4.5 5.0 0.004
Donor characteristics
Age (years ± SD) 39.5 ± 14.5 40.3 ± 14.9 <0.0001
Living donor (%) 47.3 40.3 <0.0001
Male (%) 50.4 52.0 <0.0001
African American (%) 12.4 12.6 0.524
Cold ischemia1 (h) 16.9 16.2 <0.0001
Donor HCV-positive serology1 (%) 1.7 1.4 0.008
History of hypertension1 (%) 27.7 23.1 0.008
History of diabetes mellitus1 (%) 6.1 4.8 0.007
Serum creatinine1 (mg/dl) 1.13 1.07 <0.0001
Donation after cardiac death (DCD)1 (%) 7.8 5.1 <0.0001
Extended criteria donor (ECD)1 (%) 10.3 9.7 <0.0001
Recipient–Donor characteristics
Donor–Recipient weight ratio 0.931 0.922 0.086
HLA matching (% of zero mismatch) 12.9 13.2 0.261
Donor–Recipient relationship2 <0.0001
% of biologically related 64.1 66.4
1For deceased donor only; 2for living donor only.
The recent trend in the use of a steroid-free regimen at
discharge among U.S. transplant centers is illustrated in
Figure 1. In 2000, 3.7% of recipients were discharged
on the steroid-free maintenance regimen and by 2006,
32.6% were on the steroid-free maintenance regimen at
discharge.
The adjusted death-censored graft survival at 1 and 4 years
was 96.4% and 84.6% for group 1, and 95.4% and 82.4%
for group 2, respectively. The adjusted patient survival at
1 and 4 years was 98.3% and 92.5% for group 1, and
97.7% and 90.7% for group 2, respectively. The risk of
graft failure for recipients on the steroid-free maintenance
regimen (group 1) was 22% and 17% lower than those
with steroid at 1 and 4 years, respectively (p < 0.0001).
Similarly, the risk of death for recipients on the steroid-
free maintenance regimen (group 1) was 27% and 24%
lower at 1 and 4 years, respectively, compared with re-
cipients who were discharged on the steroid-containing
maintenance regimen (p < 0.0001) (Table 2).
In the subanalysis in which living and deceased donor kid-
ney transplant recipients were evaluated with separate
multivariate Cox regression models, the observed reduced
risk for graft loss and death in the steroid-free regimen
group was more pronounced in living donor kidney trans-
plant recipients compared to the recipients of deceased
donor allograft. The risk for death-censored graft failure
was 32% lower for living and 18% lower for deceased
donor kidney recipients at 1 year and 24% lower for living
and 14% lower for deceased donor kidney transplant recip-
ients at 4 years posttransplant (p = 0.042 for the difference
at 4 years). Similarly, the risk of death was 37% lower for
living and 24% lower for deceased donor kidney recipients
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Figure 1: Trends in steroid-free im-
munosuppression at discharge for
kidney transplant recipients in U.S.
transplant centers, 2000–2006.
at 1 year and 35% lower for living and 21% lower for de-
ceased donor kidney recipients at 4 years (p = 0.002 for
the difference at 4 years)(Table 3).
The pattern on steroid usage at individual transplant cen-
ters was significantly associated with both patient and graft
survival. Using transplant centers with 95–100% steroid
usage as the reference group, the decrease in death cen-
sored graft failure appeared to be greater among the cen-
ters where steroid-free regimen was used more selec-
tively. In centers where the use of steroid-free regimen
ranged from 36% to 80% of all kidney transplant recipi-
ents in the index year, the risk of graft failure was 24% to
29% lower at 1 year and 15% to 21% lower at 4 years
(p < 0.01 for both), whereas in centers that used steroid-
free regimen in more than 80% of all kidney transplant
recipients in the index year, a lower risk of graft failure
was only seen at 1 year (12% lower than the reference
group, p = 0.01) but not 4 years (5% lower than refer-
ence group, p = 0.17). Similarly, in centers where steroid-
free regimen was utilized in 35% or less of all transplant re-
cipients in the index year, the difference in the risk of graft
failure between recipients discharged on steroid-free reg-
imen and those discharged on steroid-containing regimen
was much smaller (Figure 2A). In contrast, the increase
in the use of the steroid-free maintenance regimen at the
center level was associated with higher patient survival.
The risk of death was significantly lower in the transplant
Table 2: Graft and patient survival by the use of steroid at discharge
Group 1: Group 2:
adjusted survival (S.E.) adjusted survival (S.E.) HR (95% CI)
Outcome (N = 16491) (N = 79264) [reference = group 2]
1-year graft survival 96.4% (0.1%) 95.4% (0.1%) 0.78∗ (0.72, 0.85)
1-year patient survival 98.3% (0.1%) 97.7% (0.1%) 0.73∗ (0.65, 0.82)
4-year graft survival 84.6% (0.4%) 82.4% (0.2%) 0.83∗ (0.78, 0.87)
4-year patient survival 92.5% (0.3%) 90.7% (0.2%) 0.76∗ (0.71, 0.83)
∗p < 0.0001.
programs where more than 35% of kidney transplant re-
cipients were placed on the steroid-free regimen with a
hazard ratio of death ranging from 0.73 to 0.80 at 1 year
(p = 0.02 and p < 0.001) and from 0.76 to 0.84 (p =
0.02 and p < 0.001) at 4 years compared to recipients
discharged on the steroid-containing regimen (Figure 2B).
The use of a steroid-free maintenance immunosuppressive
regimen was associated with a higher likelihood of mon-
oclonal or polyclonal antibody induction therapy (80.6% in
group 1 vs. 66.3% in group 2, p < 0.0001) (Figure 3A and
B). The most commonly used induction agent in steroid-
free patients was rabbit antithymocyte globulin (41.8%)
followed by alemtuzumab (17.0%), basiliximab and da-
clizumab (13.9%) and others (8.0%). Compared to no anti-
body induction therapy, antibody induction therapy was not
associated with a significant difference in the 1- or 4-year
risks of graft failure or death. When analyzed individually,
the use of alemtuzumab was associated with 22% and
29% increase in risk for death-censored graft failure at 1
and 4 years (p = 0.004 and p < 0.0001, respectively) but
not death (Figure 4A and B).
The most frequently used maintenance regimen, in ad-
dition to steroid-free, was the combination of tacrolimus
and MMF. Using the combination of tacrolimus and MMF
as a reference group, the combinations of tacrolimus and
sirolimus/everolimus, cyclosporine and MMF, cyclosporine
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Table 3: Risk of graft failure and patient death for living and de-
ceased donor kidney transplant recipient by the use of steroid at
discharge
Hazard p for difference
ratio 95% CI LD1 vs. DD2
Graft 1 year DD: 0.82 0.74, 0.90 0.145
LD: 0.68 0.58, 0.81
4 years DD: 0.86 0.81, 0.92 0.042
LD: 0.76 0.69, 0.84
Patient 1 year DD: 0.76 0.67, 0.87 0.139
LD: 0.63 0.50, 0.79
4 years DD: 0.79 0.72, 0.86 0.002
LD: 0.65 0.56, 0.76
1Living donor transplant; 2deceased donor transplant.
and sirolimus/everolimus, and all others were associ-
ated with increased risks for graft failure and death at
1 and 4 years after kidney transplantation (Figure 5A
and B).
Figure 2: Hazard ratio for death cen-
sored graft failure (A) and patient death
(B) at 1 and 4 years according to the
percentage of steroid use at discharge
among individual transplant centers.
Discussion
The plausible benefits of steroid-free maintenance
immunosuppression in solid organ transplantation as docu-
mented in the literature include reduced incidence of hyper-
tension, dyslipidemia and hyperglycemia, reduced propen-
sity toward excessive posttransplant weight gain and
minimization of cosmetic, ocular and musculoskeletal com-
plications. These potential benefits have been confirmed to
a variable extent in several clinical trials in kidney transplant
recipients (13–17). However, the steroid-free immunosup-
pressive regimen may constitute inadequate immunosup-
pression in certain populations of recipients and several
clinical trials have documented an increased incidence of
early acute rejection and long-term deterioration in graft
function with the use of a steroid-free maintenance proto-
col (17–20).
The current registry-based retrospective study con-
firms a significant trend toward the increased use of
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Figure 3: Induction usage among kid-
ney transplant recipients discharged
without steroid (A) and with steroid
(B).
steroid-free maintenance immunosuppression between
2000 and 2006 in clinical transplant centers across the
United States. This trend was associated with a vari-
able pattern of steroid use as individual transplant cen-
ters discharging from 0 to 100% of their kidney trans-
Figure 4: Hazard ratio for death cen-
sored graft failure (A) and patient death
(B) at 1 and 4 years for kidney transplant
recipients receiving no steroid at dis-
charge according to various induction
agents.
plant recipients on a steroid-free maintenance regimen.
The factors governing such variability in steroid use across
centers were not explored in the current study but it
probably reflects a combination of recipient characteris-
tics and the provider-specific pattern of clinical practice.
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Figure 5: Hazard ratio for death cen-
sored graft failure (A) and patient
death (B) at 1 and 4 years for kid-
ney transplant recipients receiving
no steroid at discharge according to
the maintenance immunosuppres-
sive regimen at discharge. All reg-
imens are significantly different from
the reference group Tac/MMF at p-
value <0.0001 except where indicated
otherwise.
The wide variability in the use of steroid-free protocol in
the current study has important implications for patient
outcomes and the design of future clinical trials as this
study clearly demonstrated that the pattern of steroid use
across individual centers is itself an independent predic-
tor of both patient and graft survival. This effect of cen-
ter practice (‘center effect’) on outcomes also indicates
that there may be an aggregate threshold at each center
that demarcates the ranges of use of steroid-free regi-
men associated with better patient and graft survival. For
example, centers where less than 35% or more than
80% of recipients were discharged on steroid-free regi-
men did not have a demonstrable association between
steroid-free regimen and graft survival rates. It is open
to speculation whether center policy or patient selection,
or both is the dominant driver in centers where the use
of steroid-free regimen appears to be in the intermediate
range.
The recent increase in the use of steroid-free regimen
may have been influenced by the availability of more po-
tent immunosuppressive agents with fewer adverse ef-
fects such as derivatives of mycophenolic acid, anti-IL2R-
blocking monoclonal antibodies and antithymocyte globu-
lin. These relatively newer agents have altered the trend
in both the induction and maintenance immunosuppres-
sion strategies in a manner that appears to be related to
whether or not a steroid-free regimen should be employed.
As an illustration, the use of steroid-free regimen in the cur-
rent study was associated with a significantly higher use
of thymoglobulin inductions (41.8% vs. 24.1% thymoglob-
ulin use for steroid-free vs. steroid-containing regimen,
p < 0.0001). Thus, it seems that apart from recipient char-
acteristics, anticipated long-term maintenance immuno-
suppression governs the initial selection of an induction
regimen. In this respect, studies examining the impact and
costs associated with induction regimen may need to take
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into account the long-term regimen and outcomes asso-
ciated with the induction regimen to be able to capture a
comprehensive picture of the regimen being evaluated.
In the setting of randomized clinical trials comparing
steroid-free versus steroid-containing maintenance regi-
mens in kidney transplant, most but a few studies in the
literature showed equivalence in both graft and patient sur-
vival between the two regimens. A few studies showed
some salutary effects of steroid sparing on posttransplant
metabolic and musculoskeletal complications (14,15,17).
These studies have reported first biopsy-proven acute re-
jection rates ranging from 10 to 30% in recipients treated
with steroid-free immunosuppression and tended to oc-
cur earlier across various clinical trials (16,17,21–23) with
a second or subsequent rejection rates as high as 32%
after a successfully treated first rejection episode (24).
When protocol biopsy was performed, the cumulative in-
cidence of subclinical acute rejection and chronic allograft
nephropathy was reported to be 16–27% and 10–24%, re-
spectively, among kidney transplant recipients of a steroid-
free regimen using a combination of tacrolimus and MMF
or tacrolimus and sirolimus, at the end of 2-year follow-up
(25). It remains an open question whether modest increase
in acute rejection associated with a steroid-free mainte-
nance regimen, observed in some of those clinical trials,
will have long lasting deleterious effects on the recipient
and the allograft.
The present study is the first registry data analysis to show
that selection for de novo steroid-free maintenance im-
munosuppression does not appear to lead to any signifi-
cant decrement in patient and graft survival after account-
ing for all the major confounding factors resident in the
donor, recipient and transplant center. Indeed deceased
and living donor transplant recipients experienced a 21%
and 35% lower 4-year mortality rate, respectively, when
discharged on a steroid-free regimen compared to those
discharged on steroid-containing regimen. Both the short-
and intermediate-term graft survival rates were also higher,
albeit slightly, in the steroid-free regimen group with 1-year
and 4-year graft survival rates of 96.4% and 84.6% com-
pared to 95.4% and 82.4% in the group discharged on a
steroid-containing regimen. However, due to the presence
of selection bias that is inherent to the retrospective nature
of current study, the relationship between improved patient
and graft survival and the use of steroid-free regimen can-
not be construed and, in all likelihood, it may not be due to
the effect of steroid-free immunosuppression for several
reasons: (1) there was a significant difference in important
covariates (age, race, number of transplant, co-morbidity,
functional status, etc.) between recipients treated with a
steroid-free regimen and those who received a steroid-
containing regimen and multivariate statistical adjustment
for these differing baseline covariates might not have com-
pletely eliminated residual confounding; (2) unmeasured
important clinical characteristics between recipients in the
two comparison groups might have contributed to the dif-
ferences in graft and patient survival rates (blood pressure,
presence and severity of cardiovascular disease, level of
glycemic controls in the diabetics, etc.); (3) it is likely that re-
cipients who were constitutionally at lower risk for adverse
posttransplant outcomes were selected for the steroid-free
regimen, thus making the study findings a confirmation
of the physician’s astute clinical judgment rather than a
demonstrable benefit of the steroid-free regimen and (4) it
is also possible that steroid-containing group included kid-
ney transplant recipients who did not do well initially, thus
steroid was kept in place (such as patients with DGF, etc.).
In any event, selecting patients for steroid-free regimen
have somehow ensured better patient and graft outcomes.
In general, previous clinical trials of steroid-free regimen in
kidney transplantation have included sample size and du-
ration of follow-up that do not permit a meaningful evalua-
tion of the endpoints of patient survival, allograft survival or
cardiovascular event rates which if chosen as endpoints of
clinical trials make the studies prohibitively expensive and
infeasible. Thus, a registry study as reported herein offers
a unique methodological advantage to test the association
between treatment regimens and outcomes on a large and
diverse cohort of subjects in the ‘field’, that is, in a situa-
tion where the treatment is applied as intended outside
the contrived experimental setting which is a necessary
requirement of clinical trials. In contrast, the clinical events
occurred around the time of initial transplant surgery, not
captured by registry data, may have dictated the decision
whether or not steroid will be used, thus further patient
selection bias which cannot be solved with any analytic
method. In addition, the current study is also limited by
lack of granularity of some important and influential details
that could have an effect on the outcomes being studied.
For example, the outcome analysis was based on steroid
use at discharge in a quasi experimental ‘as treated’ fash-
ion. This approach while methodologically valid ignores the
possible changes in maintenance regimen that might have
occurred after discharge. It is well known from clinical trials
that 25–30% of recipients discharged on steroid-free reg-
imen may end up on a steroid-containing regimen during
follow-up, mostly due to occurrence of rejection. However,
this should have diluted the strength of observed associ-
ation. Similarly, some recipients who were discharged on
a steroid-containing regimen might have ended up with
a steroid-free regimen for a significant fraction of their
follow-up time as some transplant centers perform steroid
withdrawal late after transplantation. Furthermore, clinical
indications may have led to the withdrawal of steroid af-
ter discharge which would not have been captured in the
current study. Notwithstanding the potential for misclassi-
fication bias of subjects inherent to the current study, the
impact on the results is likely to be minimal since the mis-
classification is nondifferential which tends to deflate the
results toward the null (26).
In conclusion, the present data should not be interpreted
to mean that steroid-free regimen is superior to the
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alternative as the absolute differences in graft and patient
survival rates were small, albeit statistically significant with
large reduction in relative risks. The main thrust of the find-
ings is that when applied judiciously in selected kidney
transplant recipients, steroid-free regimen from the time
of discharge following the initial transplant surgery is not
associated with worse allograft and recipient outcomes. It
is unlikely that a clinical trial testing the efficacy of steroid-
free regimen on long-term outcomes will be mounted in
the near future for feasibility reasons but having shown
that steroid-free regimen is not harmful and in fact could
be beneficial in some subgroups of recipients, it is now
necessary to design prospective clinical studies that would
identify kidney transplant recipients who are not likely to
benefit from steroid-free regimen.
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